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AbstrACt
Objectives Critical and chronic illness in youth such as 
diabetes can lead to impaired mental health. Despite the 
potentially traumatic and life-threatening nature of venous 
thromboembolism (VTE), the long-term mental health of 
adolescents and young adults with VTE is unclear. We 
compared the long-term mental health of adolescents 
and young adults with VTE versus adolescents and young 
adults with insulin-dependent diabetes mellitus (IDDM) 
using psychotropic drug purchase as proxy for mental 
health.
Design Nationwide registry-based cohort study.
setting Denmark 1997–2015.
Participants All patients aged 13–33 years with an 
incident diagnosis of VTE (n=5065) or IDDM (n=6609).
Exposure First time primary hospital diagnosis of VTE or 
IDDM.
Primary and secondary outcome measures Adjusted 
absolute risk and risk difference at 1 and 5 years follow-up 
for first psychotropic drug purchase comparing patients 
with VTE and patients with IDDM.
results The absolute 1 year risk of psychotropic drug 
use was 6.2% among VTE patients versus 3.6% among 
patients with IDDM, at 5 years this was 19.3%–14.7%, 
respectively. After adjusting for the effect of sex, age and 
risk factors for VTE this corresponded to a 1 year risk 
differences of 1.9% (95 % CI 0.1% to 3.3%). At 5 years 
follow-up the risk difference was 1.9% (95% CI 0.5% to 
3.3%).
Conclusion One-fifth of adolescents and young adults 
with incident VTE had claimed a prescription for a 
psychotropic drug within 5 years, a risk comparable to that 
of young patients with IDDM.
IntrODuCtIOn
Mental comorbidity is well established as a 
prevalent problem in young patients with 
insulin-dependent diabetes mellitus (IDDM), 
with documented negative effect on disease 
management and prognosis.1–3 Venous throm-
boembolism (VTE), which include deep 
venous thrombosis (DVT) and pulmonary 
embolism (PE), is not traditionally consid-
ered a chronic illness. However, 25%–50% of 
patients with DVT live with chronic complica-
tions in terms of post-thrombotic syndrome, 
and 0.4%–4.0% of patients with PE develop 
chronic thromboembolic pulmonary hyper-
tension.4 Additionally, adolescents and young 
adults with VTE have to manage anticoagu-
lant treatment and live with the perpetual risk 
of recurrent VTE, which may reach an inci-
dence rate of 6.7 per 100 persons years among 
patients younger than 30 years.5 Thus, from a 
transition theory perspective, adolescent and 
young adults with VTE are likely to be similar 
to IDDM patients in experiencing multiple 
and simultaneous transitions, making them 
particularly vulnerable to psychosocial 
distress.6 In addition to the health-illness 
transition of VTE, the young patients will face 
the developmental transition of adolescence 
and young adulthood marked by intimacy, 
generativity and career consolidation, which 
today often continues into the early 30s.7 
strengths and limitations of this study
 ► The study included all patients aged 13–33 years 
with a first-time hospital diagnosis of venous throm-
boembolism or insulin-dependent diabetes mellitus 
in Denmark in 1997–2015.
 ► The study had complete long-term follow-up on 
psychotropic drug purchase.
 ► The study lacked data regarding socioeconomic 
position, which has been associated with increased 
mental health problems in these patient groups.
 ► Finally, the study lacked data on duration of psycho-
tropic drug use and other diseases occurring during 
follow-up, which may have been associated with the 
need for psychotropic therapy.
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Younger patients with VTE have been shown to have 
a decreased quality of life and psychological impairment 
compared with the general population of same age.8 9
Similar to IDDM patients, symptoms of anxiety and 
depression among VTE patients have been associated 
with poor disease management and mortality.10 11 Thus, 
similar to young chronically ill patients with IDDM, the 
mental health of adolescents and young adults with VTE 
could be impaired in long term.
We hypothesised that adolescents and young adults 
with VTE would have a similar risk of psychotropic drug 
purchase as chronically ill adolescents and young adults 
with IDDM. In the present nationwide cohort study, we 
therefore compared the long-term mental health of 
adolescents and young adults with VTE to young patients 
with IDDM. To assess mental health status, we used infor-
mation about psychotropic drug purchase derived from a 
Danish registry as a proxy for mental health.
MEthODs
registry data sources
We used three nationwide Danish registries in this study12: 
(1)The Danish National Patient Register, which contains 
detailed information on 99% of all somatic hospital 
admissions since 1977 along with diagnoses, coded 
according to the International Classification of Diseases 
and surgical procedures coded according to the Danish 
version of the Nordic Medico-Statistical Committee 
Classification of Surgical Procedures13; (2) The Danish 
National Prescription Registry, which contains data on 
redeemed prescriptions in Denmark since 1995, coded 
according to the Anatomical Therapeutic Chemical Clas-
sification System14 and (3) The Danish Civil Registration 
System, which holds information on gender, date of birth, 
death and emigration of all Danish residents.15 Data were 
linked using a unique civil registration number assigned 
to all Danish residents at birth or immigration and used 
in all Danish national registries.
study population
We identified all patients aged 13–33 years with a first-
time diagnosis of VTE or IDDM in the period 1 January 
1997 to 31 December 2015. Patients with VTE were iden-
tified by a first-time primary hospital diagnosis of DVT or 
PE. If a patient had a diagnosis of both DVT and PE, pref-
erence was given to PE. Risk factors for VTE included 
major surgery, fracture or trauma within 90 days before 
the VTE diagnosis or a diagnosis of cancer, inflamma-
tory bowel disease or rheumatoid arthritis within 1 year 
prior to the VTE diagnosis. Patients with IDDM were 
identified by a first-time hospital diagnosis of diabetes 
mellitus and a prescription claim for insulin within 30 
days after diagnosis and no insulin prescription before 
30 days prior to date of diagnosis. The index date for 
IDDM patients was defined as the date of first insulin 
prescription purchase after the diabetes diagnosis. The 
index date for VTE patients was based on day of VTE 
diagnosis and randomly shifted according to the distri-
bution of time between diabetes diagnosis and insulin 
prescription purchase in the IDDM cohort. We excluded 
patients who had not been residents in Denmark for at 
least 2 years before the date of VTE or IDDM in order 
to ensure sufficient lookback time for diagnoses and 
medications, as well as patients who died on the day of 
diagnosis. To identify new-onset impaired mental health, 
we further excluded patients with prior psychiatric 
diagnosis (depression, anxiety, bipolar disorder, schizo-
phrenia and addiction) and patients who had purchased 
psychotropic drugs (antidepressants, anxiolytics, seda-
tives, antipsychotics) within 2 years before the date of 
VTE or IDDM diagnosis. Further, we excluded patients 
with gestational diabetes mellitus and pregnancy-related 
VTE because of the distinct clinical course of pregnan-
cy-related VTE and gestational diabetes, as well the risk 
of postpartum depression. Online supplementary table 1 
provides information on codes used in the study.
Outcome
The primary endpoint was a composite endpoint of 
psychotropic drug purchase, as a proxy for impaired 
mental health, recorded in the Danish National Prescrip-
tion Registry following the index date. The secondary 
outcome was the specific types of psychotropic drugs: 
antipsychotics, anxiolytics, sedatives and antidepressants.
statistical analysis
Descriptive characteristics of the study population at 
date of diagnosis of VTE or IDDM were presented using 
means and SD for continuous measures and counts 
and percentages for categorical measures. Time to first 
psychotropic drug purchase was measured from index 
date. Patients were censored at the time of death, emigra-
tion or end of study (31 December 2015), whichever 
came first. Cumulative incidence functions (by means 
of the Aalen-Johansen estimator), assuming death as 
competing risks, were used to depict risk of psychotropic 
drug purchase within 10 years. We used pseudo-value 
regression approach with identity link function on a risk 
difference scale to assess the association between diag-
nosis type (VTE or IDDM) and the risk of a psychotropic 
drug purchase within 1 and 5 years taking into account 
the competing risk of death. The pseudo-value regres-
sion technique reduces to simple regression on the event 
status indicator when there is no censoring and accounts 
for censored observations before 1 and 5 years, respec-
tively.16 To assess to which extent the observed association 
could be explained by sex, age or recent provocation, we 
also conducted multivariate regression of pseudovalues, 
adjusting for the effect of sex (binary), age (continuous) 
and ‘recent provocation’ (binary). We repeated the 
analysis with stratification according to sex, age (13–25 
or 26–33 years) VTE type (DVT or PE) and VTE-status 
(provoked or unprovoked).
Stata/MP V.13 was used for the statistical analysis.
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Patient and public involvement
Patients and public were not directly involved in the 
development of the research question and outcome 
measures or design of this nationwide cohort study.
rEsults
We identified 6297 patients with VTE and 7616 patients with 
IDDM. After exclusion of patients who died on the day of 
diagnosis and patients with prior psychiatric diagnoses or a 
psychotropic drug purchase within 2 years prior to the diag-
nosis, the study population comprised 5065 VTE patients, of 
which 76.6% had DVT and 23.4% had PE, and 6609 IDDM 
patients (figure 1). Patients with VTE were slightly older 
compared with patients with IDDM (mean age 25.7 years 
vs 23.7 years), and a substantially higher proportion were 
females (68.5% vs 38.1%) (table 1). Approximately one-fifth 
of patients with VTE had an underlying recorded risk factor, 
such as trauma (12.2%) or major surgery (12.9%). In 
comparison, only 4.0% of patients with IDDM had a diag-
nosis of trauma, and 2.4% had major surgery (table 1).
The absolute risk of psychotropic drug use among patients 
with VTE was 6.2% at 1 year of follow-up and 19.3% after 5 
years of follow-up. The cumulative incidence curve revealed 
a higher risk of psychotropic drugs among patients with 
VTE compared with patients with IDDM (figure 2). At 1 year 
follow-up, the crude risk difference was 2.6% (95 % CI 1.3% 
to 3.9%). Extending follow-up to 5 years did not materially 
change this conclusion; the crude 5-year risk difference 
was 4.6% (95% CI 2.3% to 6.9%) (table 2). The finding of 
a higher psychotropic drug use among patients with VTE 
compared with IDDM was attenuated when adjusting for 
the effect of sex, age and risk factors for VTE (1 year risk 
difference 1.9%, 95% CI 0.1% to 3.3%; 5 year risk difference 
1.9%, 95% CI 0.5% to 3.3%). Analyses stratified by sex, age, 
presence of provoking factors (table 2), also revealed slightly 
increased 5-year adjusted risk of psychotropic drug purchase 
among VTE patients compared with IDDM patients, though 
the risk differences were not statistically significant except 
Figure 1 Flowchart of patients included in the final study population.
Table 1 Study population characteristics
Variable VTE IDDM
  N 5065 6609
  Mean age (SD) 25.7 (5.2) 23.7 (6.5)
  Age group, n (%)
   13–25 years 2258 (44.6) 3627 (54.9)
   26–33 years 2807 (54.4) 2982 (45.1)
  Females, n (%) 3470 (68.5) 2516 (38.1)
  Risk factor for VTE, yes, n (%) 1179 (23.3) 449 (6.8)
   Trauma 618 (12.2) 267 (4.0)
   Surgery 652 (12.9) 156 (2.4)
   Cancer 64 (1.3) 16 (0.2)
   Inflammatory bowel disease 49 (1.0) 26 (0.7)
   Rheumatoid arthritis 8 (0.1) 5 (0.1)
  DVT, n (%) 3881 (76.6) –
  PE, n (%) 1184 (23.4) – 
DVT, deep venous thrombosis; IDDM, insulin-dependent 
diabetes mellitus; PE, pulmonary embolism; VTE, venous 
thromboembolism.
Figure 2 Cumulative incidence of psychotropic drug 
purchase in patients with venous thromboembolism 
and patients with insulin-dependent diabetes 
mellitus. IDDM, insulin-dependent diabetes mellitus; 
VTE, venous thromboembolism.
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for males in whom the long-term risk of psychotropic drugs 
was significantly higher among the VTE patients (table 2).
Antidepressants were the most frequently purchased 
drug class in both patient groups (VTE: 48%, IDDM: 58%) 
followed by sedatives (VTE: 24%, IDDM: 20%), anxiolytics 
(VTE: 19%, IDDM: 13%), antipsychotics (VTE: 5%, IDDM: 
6%) and combined prescription of more than one drug class 
(VTE: 3% IDDM 3%). The absolute risk and risk difference 
comparing VTE patients and IDDM patients stratified by 
psychotropic drug class did not materially change the overall 
conclusions (data not shown).
DIsCussIOn
To our knowledge, this is the first study to compare the 
mental health of adolescents and young adults with VTE to 
that of patients receiving a diagnosis of a chronic disease 
such as IDDM. Our nationwide cohort study revealed that 
the long-term mental health of adolescents and young 
adults with VTE was comparable to that of IDDM patients 
as evidenced by a slightly higher risk of psychotropic drug 
use among the VTE patients, which persisted over time 
and was evident across strata of age and type of VTE.
Our findings extend the results from previous studies, 
indicating that mental health impairment does not 
diminish over time among VTE patients.9 17 18 Compared 
with IDDM patients among whom long-term comorbid 
mental health problems are well documented,1 3 we 
noted comparable psychotropic use among patients with 
VTE. Indeed, our study revealed that one-fifth of adoles-
cents and young adults with VTE claim a prescription 
for a psychotropic drug within 5 years. This is of major 
concern, as it is well established that impaired mental 
health has an effect on outcome as well as disease manage-
ment in medically ill patients.19 Accordingly, symptoms of 
depression and anxiety among VTE patients have been 
associated with both increased mortality and poor disease 
management.10 11 Thus, impaired mental health possibly 
plays an important role for disease management and long-
term prognosis in a considerable number of young VTE 
patients as the proportion with impaired mental health 
was comparable to that of patients with IDDM. These 
findings indicate a need for further studies to prevent, 
or at least, to minimise psychological distress in patients 
with VTE.
At odds with studies from the general population, 
where higher levels of depression and lower quality of life 
are found in women than men,20 we found no difference 
in psychotropic drug use among men and women with 
VTE. This lack of gender-related differences in mental 
health following VTE is in accordance with prior obser-
vations of mental quality of life following VTE,21–23 and 
subject to further investigation.
study limitations
Misclassification of VTE and IDDM diagnoses cannot 
be ruled out. Danish validation studies have previously 
found a positive predictive value of the VTE diagnosis of 
88% to 90%,24 25 and ascertainment of diabetes mellitus 
by purchase of insulin in combination with a primary 
hospital discharge diagnosis has been shown to have a 
positive predictive value of 95%–97%.26 27 We defined 
impaired mental health by prescription purchase of 
psychotropic drugs but do not know whether the patients 
actually took the medication. However, in the present 
study, we infer that a prescription for a psychotropic drug 
would be an indication of impaired mental health. We 
did not assess the duration of psychotropic drug use and 
other diseases occurring during follow-up, which may 
have been associated with the need for psychotropic 
Table 2 Risk of psychotropic drug purchase following a diagnosis of venous thromboembolism or insulin dependent diabetes 
mellitus in youth or adolescence
Characteristic














VTE vs IDDM 
(95% CI)
VTE vs IDDM 
(95% CI) VTE IDDM
VTE vs IDDM 
(95% CI)
VTE vs IDDM 
(95% CI)
Overall 6.2 3.6 2.6 (1.3 to 3.9) 1.9 (0.1 to 3.3) 19.3 14.7 4.6 (2.3 to 6.9) 1.9 (0.5 to 3.3)
Male 6.9 2.9 4.1 (1.8 to 6.4) 3.0 (0.7 to 5.4) 18.5 11.9 6.6 (2.7 to 10.4) 3.0 (0.7 to 5.4)
Female 5.9 4.9 1.0 (−0.1 to 2.7) 0.3 (−1.5 to 2.1) 19.7 19.5 0.2 (−2.9 to 3.4) 0.3 (−0.2 to 2.1)
Age 13–25 years 6.1 2.7 3.4 (1.5 to 5.2) 1.7 (0.1 to 3.7) 17.9 12.9 5.1 (1.9 to 8.3) 1.7 (−0.4 to 3.7)
Age 26–33 years 6.4 4.8 1.5 (−0.3 to 3.4) 0.7 (−0.1 to 2.8) 20.4 17.1 3.4 (0.1 to 6.8) 0.7 (−0.0 to 2.8)
Provoked VTE 6.3 3.6 2.4 (−0.2 to 5.0) 1.1 (−0.2 to 3.9) 18.8 14.7 4.1 (−0.7 to 8.9) 1.1 (−0.6 to 3.9)
Unprovoked VTE 6.0 3.6 2.7 (1.2 to 4.1) 1.5 (−0.1 to 3.0) 19.5 14.7 4.8 (1.6 to 6.8) 1.5 (−0.1 to 3.0)
DVT 6.1 3.6 2.6 (1.2 to 4.1) 1.2 (−0.1 to 2.7) 18.9 14.7 4.1 (1.2 to 4.1) 1.2 (−0.1 to 2.7)
PE 6.3 3.6 2.4 (0.1 to 5.0) 1.0 (−0.2 to 3.6) 20.8 14.7 6.1 (1.7 to 10.6) 0.9 (−0.7 to 3.6)
*Adjusted for sex, age, recent provocation (trauma, surgery, cancer, inflammatory bowel disease or rheumatoid arthritis) except when 
stratifying variable.
DVT, deep venous thrombosis; IDDM, insulin-dependent diabetes mellitus; PE, pulmonary embolism; VTE, venous thromboembolism.
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therapy. We also lacked data on socioeconomic factors. 
Low socioeconomic position has been associated with 
increased mental health problems, for example, higher 
depression rates among young patients with IDDM28 
and low health related quality of life in young women 
with pregnancy-related DVT.29 Given these limitations, 
it is important to emphasise that based on this observa-
tional study we cannot infer a causal interpretation of the 
observed association between VTE and impaired mental 
health.
The major strengths of this study are the large sample 
size and complete coverage in the Danish hospital 
discharge and prescription purchase registries including 
all inpatient and outpatients with VTE or IDDM, which 
enabled a complete long-term follow-up on psychotropic 
drug purchases.
COnClusIOn
This nationwide cohort study showed that one-fifth of 
adolescents and young adults with incident VTE had 
claimed a prescription for a psychotropic drug within 5 
years, indicating an impact on mental health comparable 
to that of young patients with IDDM.
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